Salute e Benessere
Recalculation of warrants of series TO 2 following rights issue
The terms and conditions for the warrants, including potential adjustments due to future share issues, are available on the Company's website.
Pia Renaudin , CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden , SciBase is a leader in dermatological advancements.
The Company has been listed on Nasdaq First North Growth Market since June 2, 2015 , and the Certified Advisor is Carnegie Investment Bank AB (publ). For more information, visit www.SciBase.com. All press releases and financial reports can be found here: http://investors.scibase.se/sv/pressmeddelanden .
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/scibase/r/recalculation-of-warrants-of-series-to-2-following-rights-issue,c4095904
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/recalculation-of-warrants-of-series-to-2-following-rights-issue-302360593.html